Michelsen Sissel, Nachi Salma, Van Dyck Walter, Simoens Steven, Huys Isabelle
Clinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium.
Healthcare Management Centre, Vlerick Business School, Ghent, Belgium.
Front Pharmacol. 2020 Dec 8;11:594446. doi: 10.3389/fphar.2020.594446. eCollection 2020.
The challenging market access of high-cost one-time curative therapies has inspired the development of alternative reimbursement structures, such as outcome-based spread payments, to mitigate their unaffordability and answer remaining uncertainties. This study aimed to provide a broad overview of barriers and possible opportunities for the practical implementation of outcome-based spread payments for the reimbursement of one-shot therapies in European healthcare systems. A systematic literature review was performed investigating published literature and publicly available documents to identify barriers and implementation opportunities for both spreading payments and for implementing outcome-based agreements. Data was analyzed via qualitative content analysis by extracting data with a reporting template. A total of 1,503 publications were screened and 174 were included. Main identified barriers for the implementation of spread payments are reaching an agreement on financial terms while considering 12-months budget cycles and the possible violation of corresponding international accounting rules. Furthermore, outcome correction of payments is currently hindered by the need for additional data collection, the lack of clear governance structures and the resulting administrative burden and cost. The use of spread payments adjusted by population- or individual-level data collected within automated registries and overseen by a governance committee and external advisory board may alleviate several barriers and may support the reimbursement of highly innovative therapies. High-cost advanced therapy medicinal products pose a substantial affordability challenge on healthcare systems worldwide. Outcome-based spread payments may mitigate the initial budget impact and alleviate existing uncertainties; however, their effective implementation still faces several barriers and will be facilitated by realizing the required organizational changes.
高成本一次性治愈性疗法面临的具有挑战性的市场准入问题,促使人们开发替代性的报销结构,如基于结果的分期支付,以缓解其难以承受的成本,并应对尚存的不确定性。本研究旨在全面概述在欧洲医疗体系中,基于结果的分期支付用于一次性疗法报销的实际实施所面临的障碍和可能的机遇。开展了一项系统性文献综述,对已发表文献和公开可得文件进行调查,以确定分期支付以及实施基于结果的协议的障碍和实施机遇。通过使用报告模板提取数据,采用定性内容分析法对数据进行分析。共筛选了1503篇出版物,纳入了174篇。确定的分期支付实施的主要障碍包括,在考虑12个月预算周期的同时就财务条款达成一致,以及可能违反相应的国际会计准则。此外,目前支付的结果校正受到额外数据收集需求、缺乏明确治理结构以及由此产生的行政负担和成本的阻碍。使用根据自动登记系统内收集的人群或个人层面数据进行调整、并由治理委员会和外部咨询委员会监督的分期支付,可能会缓解一些障碍,并可能支持对高度创新疗法的报销。高成本的先进治疗药物给全球医疗体系带来了巨大的可承受性挑战。基于结果的分期支付可能会减轻初始预算影响并缓解现有不确定性;然而,其有效实施仍面临若干障碍,实现所需的组织变革将有助于促进实施。